Company Analysis
Sign in

Phio Pharmaceuticals Corp. (PHIO)

Nasdaq: PHIO · Pharmaceutical Preparations · King Of Prussia, PA · filing with the SEC since 2011
Full chart Alerts Compare
Grade4.0
◀ Past 1.3● Present 4.6▶ Future 5.2
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Phio Pharmaceuticals Corp.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
49
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
Biotechnology5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
RXi Pharmaceuticals Corporation a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
17 granted
26 published
Phio Pharmaceuticals Corp. its own name
US, as the owner printed on each patent. 3 more under the same name are not counted (printed in NZ)
22 granted
14 published
RXi Pharmaceuticals Corporation a former name
named as the applicant on its applications, in US
0 granted
6 published
Phio Pharmaceuticals Corp. its own name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 12, 202411,926,828Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1PharmaceuticalsPhio Pharmaceuticals Corp.
Jun 6, 202311,667,915RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityBiotechnologyPhio Pharmaceuticals Corp.
Feb 21, 202311,584,933RNA interference in ocular indicationsPharmaceuticalsPhio Pharmaceuticals Corp.
Jul 26, 202211,396,654Neutral nanotransportersPharmaceuticalsPhio Pharmaceuticals Corp.
Mar 22, 202211,279,934Methods for treating cancer using nucleic acids targeting MDM2 or MYCNBiotechnologyPhio Pharmaceuticals Corp.
Feb 22, 202211,254,940Inhibition of MAP4K4 through RNAiPharmaceuticalsPhio Pharmaceuticals Corp.
Sep 14, 202111,118,178Reduced size self-delivering RNAI compoundsBiotechnologyPhio Pharmaceuticals Corp.
Jun 1, 202111,021,707Reduced size self-delivering nucleic acid compounds targeting long non-coding RNABiotechnologyPhio Pharmaceuticals Corp.
May 11, 202111,001,845Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PharmaceuticalsPhio Pharmaceuticals Corp.
Mar 2, 202110,934,550Immunotherapy of cancerBiotechnologyPhio Pharmaceuticals Corp.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 12, 20242024/0301430CHEMICALLY MODIFIED OLIGONUCLEOTIDESBiotechnologyPhio Pharmaceuticals Corp.
Mar 23, 20232023/0089478CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERYBiotechnologyPhio Pharmaceuticals Corp.
Jan 5, 20232023/0002766CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPYBiotechnologyPhio Pharmaceuticals Corp.
Nov 11, 20212021/0348169METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1PharmaceuticalsPhio Pharmaceuticals Corp. · patent 11,926,828 granted from it
Nov 11, 20212021/0348166IMMUNOTHERAPY OF CANCERBiotechnologyPhio Pharmaceuticals Corp.
Aug 26, 20212021/0261968RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONSPharmaceuticalsPhio Pharmaceuticals Corp.
May 20, 20212021/0147849REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDSPharmaceuticalsPhio Pharmaceuticals Corp.
Mar 4, 20212021/0062195RNA INTERFERENCE IN OCULAR INDICATIONSPharmaceuticalsPhio Pharmaceuticals Corp. · patent 11,584,933 granted from it
Oct 1, 20202020/0308578RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITYBiotechnologyPhio Pharmaceuticals Corp. · patent 11,667,915 granted from it
Jul 9, 20202020/0215113CHEMICALLY MODIFIED OLIGONUCLEOTIDESPharmaceuticalsPhio Pharmaceuticals Corp.
What it applied for, 2024 to 2025: Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PHIO · research, not advice